학술논문

A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome
Document Type
Article
Source
In: Blood. (Blood, 2 March 2023, 141(9):971-983)
Subject
Language
English
ISSN
15280020
00064971